Key facts
- Apeximmune’s last known valuation is $62.7M (Apr 2025).
- It has raised $32.8M; the latest was Later Stage VC ($21.3M) in Apr 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Taya Venture Capital, DCI Partners, Hercules Bioventures, Huahai US — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Apeximmune
- ·The full record, as it builds
Funding rounds
No funding rounds for Apeximmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apeximmune
Developer of novel biologics designed to modulate the immune system. The company's platform combines bioinformatics with biological assays to enable the identification of novel immune-modulating targets and the development of biologics/antibodies to treat disease through these mechanisms, enabling healthcare professionals to provide treatment for a broad spectrum of indications, including cancer, autoimmune disease and transplantation.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2016
- Employees
- 6
- Website
- apeximmune.com/
- Ownership
- Privately Held (backing)
Apeximmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apeximmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apeximmune in its N-PORT filings yet. We sweep new filings monthly.